ODI Pharma (ODI) Q3 24/25 earnings summary

Executive summary

• Net sales for Q3 2025 were SEK 2.93 million, down sharply from SEK 13.86 million in Q3 2024; nine-month sales were SEK 3.06 million versus SEK 14.78 million year-over-year.

• Q3 2025 net loss was SEK 340,612 compared to a profit of SEK 1.39 million in Q3 2024; nine-month loss was SEK 4.15 million versus a profit of SEK 0.96 million year-over-year.

• Limited product deliveries in Q3 due to import license issues, now resolved; order volumes expected to increase and profitability anticipated to return in the near term.

• CEO transition: Jan-Mark Edewaard took over as CEO on January 1, 2025, bringing over 25 years of leadership experience.

Financial highlights

• Q3 2025 operating income was SEK -215,319, down from SEK 1,578,134 in Q3 2024.

• Cash flow from operations for Q3 2025 was SEK -174,539, compared to SEK 1,797,658 in Q3 2024.

• Cash and cash equivalents at March 31, 2025, were SEK 2.00 million, down from SEK 5.93 million a year earlier.

• Total assets at quarter-end were SEK 7.38 million, down from SEK 15.46 million at the same time last year.

• No long-term liabilities; all liabilities are current.

Outlook and guidance

• With import license issues resolved, increased order volumes and a return to profitability are expected over the course of the year.

• The company aims to expand its presence in regulated European cannabis markets through a capital-efficient, partner-led model.